{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:00:46Z","timestamp":1791262846904,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Complement-dependent cytotoxicity is thought to be an important mechanism of action of the anti-CD20 monoclonal antibody rituximab. This study investigates the sensitivity of freshly isolated cells obtained from 33 patients with B-cell chronic lymphocytic leukemia (B-CLL), 5 patients with prolymphocytic leukemia (PLL), and 6 patients with mantle cell lymphoma (MCL) to be lysed by rituximab and complement in vitro. The results showed that in B-CLL and PLL, the levels of CD20, measured by standard immunofluorescence or using calibrated beads, correlated linearly with the lytic response (coefficient greater than or equal to 0.9;P\u2009&amp;lt;\u2009.0001). Furthermore, the correlation remained highly significant when the 6 patients with MCL were included in the analysis (coefficient 0.91; P\u2009&amp;lt;\u2009.0001), which suggests that CD20 levels primarily determine lysis regardless of diagnostic group. The role of the complement inhibitors CD46, CD55, and CD59 was also investigated. All B-CLL and PLL cells expressed these molecules, but at different levels. CD46 was relatively weak on all samples (mean fluorescence intensity less than 100), whereas CD55 and CD59 showed variability of expression (mean fluorescence intensity 20-1200 and 20-250, respectively). Although CD55 and CD59 levels did not permit prediction of complement susceptibility, the functional block of these inhibitors demonstrated that they play an important role in regulating complement-dependent cytotoxicity. Thus, lysis of poorly responding B-CLL samples was increased 5- to 6-fold after blocking both CD55 and CD59, whereas that of high responders was essentially complete in the presence of a single blocking antibody. These data demonstrate that CD20, CD55, and CD59 are important factors determining the in vitro response to rituximab and complement and indicate potential strategies to improve the clinical response to this biologic therapy.<\/jats:p>","DOI":"10.1182\/blood.v98.12.3383","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:40Z","timestamp":1027759600000},"page":"3383-3389","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":354,"title":["CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59"],"prefix":"10.1182","volume":"98","author":[{"given":"Jose\u0301e","family":"Golay","sequence":"first","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Lazzari","sequence":"additional","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Facchinetti","sequence":"additional","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmaria","family":"Borleri","sequence":"additional","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Introna","sequence":"additional","affiliation":[{"name":"From the Laboratory of Molecular Immunohematology, Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy; and the Division of Hematology, Ospedali Riuniti, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222135324300_B1","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin Oncol."},{"key":"2020021222135324300_B2","first-page":"74","article-title":"Preclinical and phase I and II trials of rituximab.","volume":"26","author":"Maloney","year":"1999","journal-title":"Semin Oncol."},{"key":"2020021222135324300_B3","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.","volume":"26","author":"Czuczman","year":"1999","journal-title":"Semin Oncol."},{"key":"2020021222135324300_B4","first-page":"79","article-title":"Rituximab in indolent lymphoma: the single-agent pivotal trial.","volume":"26","author":"McLaughlin","year":"1999","journal-title":"Semin Oncol."},{"key":"2020021222135324300_B5","first-page":"52","article-title":"The role of Campath-1 antibodies in the treatment of lymphoid malignancies.","volume":"26","author":"Dyer","year":"1999","journal-title":"Semin Oncol."},{"key":"2020021222135324300_B6","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood."},{"key":"2020021222135324300_B7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med."},{"key":"2020021222135324300_B8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0167-5699(00)01669-8","article-title":"Clinical trials of antibody therapy.","volume":"21","author":"Glennie","year":"2000","journal-title":"Immunol Today."},{"key":"2020021222135324300_B9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1042\/bst0250705","article-title":"Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.","volume":"25","author":"Anderson","year":"1997","journal-title":"Biochem Soc Trans."},{"key":"2020021222135324300_B10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med."},{"key":"2020021222135324300_B11","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.","volume":"95","author":"Golay","year":"2000","journal-title":"Blood."},{"key":"2020021222135324300_B12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol."},{"key":"2020021222135324300_B13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.","volume":"91","author":"Shan","year":"1998","journal-title":"Blood."},{"key":"2020021222135324300_B14","first-page":"7170","article-title":"Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signalling pathways.","volume":"60","author":"Mathas","year":"2000","journal-title":"Cancer Res."},{"key":"2020021222135324300_B15","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood.V97.5.1392","article-title":"Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.","volume":"97","author":"Ghetie","year":"2001","journal-title":"Blood."},{"key":"2020021222135324300_B16","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood."},{"key":"2020021222135324300_B17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021222135324300_B18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood."},{"key":"2020021222135324300_B19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021222135324300_B20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-1759(97)00002-1","article-title":"A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody.","volume":"202","author":"Gazzano-Santoro","year":"1997","journal-title":"J Immunol Methods."},{"key":"2020021222135324300_B21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.1998.tb00995.x","article-title":"Clinico-prognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins.","volume":"60","author":"Molica","year":"1998","journal-title":"Eur J Haematol."},{"key":"2020021222135324300_B22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias.","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol."},{"key":"2020021222135324300_B23","first-page":"499","article-title":"Membrane attack complex (MAC)\u2013mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins.","volume":"75","author":"Rooney","year":"1992","journal-title":"Immunology."},{"key":"2020021222135324300_B24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol."},{"key":"2020021222135324300_B25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1046\/j.1365-2141.2000.109004900.x","article-title":"Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine.","volume":"109","author":"Hoffman","year":"2000","journal-title":"Br J Haematol."},{"key":"2020021222135324300_B26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0065-2776(08)60868-8","article-title":"Control of the complement system.","volume":"61","author":"Liszewski","year":"1996","journal-title":"Adv Immunol."},{"key":"2020021222135324300_B27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","article-title":"Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.","volume":"62","author":"Yang","year":"1999","journal-title":"Am J Hematol."},{"key":"2020021222135324300_B28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/12\/3383\/1678222\/h8230103383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/12\/3383\/1678222\/h8230103383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:16:07Z","timestamp":1581545767000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/12\/3383\/53138\/CD20-levels-determine-the-in-vitro-susceptibility"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,1]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2001,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.12.3383","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12,1]]}}}